Evaluation of single bolus, dual-echo dynamic susceptibility contrast MRI protocols in brain tumor patients
Relative cerebral blood volume (rCBV) obtained from dynamic susceptibility contrast (DSC) MRI is adversely impacted by contrast agent leakage in brain tumors. Using simulations, we previously demonstrated that multi-echo DSC-MRI protocols provide improvements in contrast agent dosing, pulse sequence flexibility, and rCBV accuracy. The purpose of this study is to assess the in-vivo performance of dual-echo acquisitions in patients with brain tumors (n = 59). To verify pulse sequence flexibility, four single-dose dual-echo acquisitions were tested with variations in contrast agent dose, flip angle, and repetition time, and the resulting dual-echo rCBV was compared to standard single-echo rCBV obtained with preload (double-dose). Dual-echo rCBV was comparable to standard double-dose single-echo protocols (mean (standard deviation) tumor rCBV 2.17 (1.28) vs. 2.06 (1.20), respectively). High rCBV similarity was observed (CCC = 0.96), which was maintained across both flip angle (CCC = 0.98) and repetition time (CCC = 0.96) permutations, demonstrating that dual-echo acquisitions provide flexibility in acquisition parameters. Furthermore, a single dual-echo acquisition was shown to enable quantification of both perfusion and permeability metrics. In conclusion, single-dose dual-echo acquisitions provide similar rCBV to standard double-dose single-echo acquisitions, suggesting contrast agent dose can be reduced while providing significant pulse sequence flexibility and complementary tumor perfusion and permeability metrics.
Brain tumors, dual-echo, dynamic susceptibility contrast (DSC), perfusion, permeability
Journal of Cerebral Blood Flow and Metabolism
Digital Object Identifier (DOI)
Stokes, Ashley M.; Bergamino, Maurizio; Alhilali, Lea; Hu, Leland S.; Karis, John P.; Baxter, Leslie C.; Bell, Laura C.; and Quarles, C. Chad, "Evaluation of single bolus, dual-echo dynamic susceptibility contrast MRI protocols in brain tumor patients" (2021). Translational Neuroscience. 1184.